ArticleApplied and environmental microbiology2012
Preliminary safety evaluation of a new Bacteroides xylanisolvens isolate.
Article in Applied and environmental microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- Population scale analysis reveals gut microbiome diversity and functional shifts linked to obesity.iScience · 2026Article
- Article
- Serotonergic and immunomodulatory properties of the psychobiotic candidateApplied and environmental microbiology · 2025Article
- Article
- Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm.Probiotics and antimicrobial proteins · 2025Review
- Akkermansia muciniphila isolated from forest musk deer ameliorates diarrhea in mice via modification of gut microbiota.Animal models and experimental medicine · 2025Article
- Genome- and Toxicology-Based Safety Assessment of ProbioticFoods (Basel, Switzerland) · 2024Article
- Characterization and Preliminary Safety Evaluation ofFoods (Basel, Switzerland) · 2024Article
- Article
- Gut microbiota resilience and recovery after anticancer chemotherapy.Microbiome research reports · 2023Review
- Novel Candidate Microorganisms for Fermentation Technology: From Potential Benefits to Safety Issues.Foods (Basel, Switzerland) · 2022Review
- Article
- Gut microbiota dysbiosis in Chinese children with type 1 diabetes mellitus: An observational study.World journal of gastroenterology · 2021Observational
- Isolation and characterisation of ΦcrAss002, a crAss-like phage from the human gut that infects Bacteroides xylanisolvens.Microbiome · 2021Article
- Causal effects in microbiomes using interventional calculus.Scientific reports · 2021Article
- Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever.Journal of inflammation research · 2021Article
- Recent Advancements in the Development of Modern Probiotics for Restoring Human Gut Microbiome Dysbiosis.Indian journal of microbiology · 2020Review
- Commensal Obligate Anaerobic Bacteria and Health: Production, Storage, and Delivery Strategies.Frontiers in bioengineering and biotechnology · 2020Review
- Pilot Safety Evaluation of a Novel Strain ofFrontiers in genetics · 2018Article
- Next-generation probiotics: the spectrum from probiotics to live biotherapeutics.Nature microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides conferring some health benefit to the host, a bacterial strain must present an unambiguous safety status to be considered a probiotic. We here present the preliminary safety evaluation of a new Bacteroides xylanisolvens strain (DSM 23964) isolated from human feces. First results suggest that it may be able to provide probiotic health benefits. Its identity was confirmed by biochemical analysis, by sequencing of its 16S rRNA genes, and by DNA-DNA hybridization. Virulence determinants known to occur in the genus Bacteroides, such the bft enterotoxin and other enzymatic activities involved in the degradation of the extracellular matrix and the capsular polysaccharide PS A, were absent in this strain. The investigation of the antibiotic susceptibility indicated that strain DSM 23964 was sensitive to metronidazole, meropenem agents, and clindamycin. Resistance to penicillin and ampicillin was identified to be conferred by the β-lactamase cepA gene and could therefore be restored by adding β-lactamase inhibitors. The localization of the cepA gene in the genome of strain DSM 23964 and the absence of detectable plasmids further suggest that a transfer of β-lactamase activity or the acquisition of other antibiotic resistances are highly improbable. Taken together, the presented data indicate that the strain B. xylanisolvens DSM 23964 has no virulence potential. Since it also resists the action of gastric enzymes and low-pH conditions, this strain is an interesting candidate for further investigation of its safety and potential health-promoting properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.